WORLDWIDE EXPERIENCE OF METFORMIN AS AN EFFECTIVE GLUCOSE-LOWERING AGENT - A METAANALYSIS

[1] Colwell JA, Is it time to introduce metformin in the US?, Diabetes Care, 16, pp. 653-655, (1993)

[2] Bloomgarden ZT, The American Diabetes Association Annual Meeting, 1994: Treatment issues for NIDDM, Diabetes Care, 17, pp. 1078-1084, (1994)

[3] Campbell IW, Management of type 2 diabetes mellitus with special reference to metformin therapy, Diabete Metab, 17, pp. 191-196, (1991)

[4] Bailey CJ, Metformin: an update, Gen Pharmacol, 24, pp. 1299-1309, (1993)

[5] Nagi DK, Yudkin JS, Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects, Diabetes Care, 16, pp. 621-629, (1993)

[6] Campbell IW, Sulphonylureas and metformin: efficacy and inadequacy, New Antidiabetic Drugs, pp. 33-51, (1990)

[7] Hedges LV, Olkin I, Statistical Methods for Meta‐analysis, (1985)

[8] Clarke BF, Duncan LJP, Comparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetics, Lancet, 1, pp. 123-126, (1968)

[9] Clarke BF, Campbell IW, Comparison of metformin and chlorpropamide in non‐obese, maturity‐onset diabetics uncontrolled by diet, Br Med J, 2, pp. 1576-1578, (1977)

[10] Reduction in HbAl_c with basal insulin supplement, sulfonylurea, or biguamide therapy in maturity‐onset diabetes: a multicenter study, Diabetes, 34, pp. 793-798, (1985)

[1] Colwell JA, Is it time to introduce metformin in the US?, Diabetes Care, 16, pp. 653-655, (1993)

[2] Bloomgarden ZT, The American Diabetes Association Annual Meeting, 1994: Treatment issues for NIDDM, Diabetes Care, 17, pp. 1078-1084, (1994)

[3] Campbell IW, Management of type 2 diabetes mellitus with special reference to metformin therapy, Diabete Metab, 17, pp. 191-196, (1991)

[4] Bailey CJ, Metformin: an update, Gen Pharmacol, 24, pp. 1299-1309, (1993)

[5] Nagi DK, Yudkin JS, Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects, Diabetes Care, 16, pp. 621-629, (1993)

[6] Campbell IW, Sulphonylureas and metformin: efficacy and inadequacy, New Antidiabetic Drugs, pp. 33-51, (1990)

[7] Hedges LV, Olkin I, Statistical Methods for Meta‐analysis, (1985)

[8] Clarke BF, Duncan LJP, Comparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetics, Lancet, 1, pp. 123-126, (1968)

[9] Clarke BF, Campbell IW, Comparison of metformin and chlorpropamide in non‐obese, maturity‐onset diabetics uncontrolled by diet, Br Med J, 2, pp. 1576-1578, (1977)

[10] Reduction in HbAl_c with basal insulin supplement, sulfonylurea, or biguamide therapy in maturity‐onset diabetes: a multicenter study, Diabetes, 34, pp. 793-798, (1985)